The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)
Open accessAbstract
Zoledronic acid 5 mg (ZOL) annually for 3 years reduces fracture risk in postmenopausal women with osteoporosis. To investigate long-term effects of ZOL on bone mineral density (BMD) and fracture risk, the Health Outcomes and Reduced Incidence with Zoledronic acid Once Yearly–Pivotal Fracture Trial (HORIZON-PFT) was extended to 6 years. In this international, multicenter, double-blind, placebo-controlled extension trial, 1233 postmenopausal women who received ZOL for 3 years in the core study were randomized to 3 additional years of ZOL (Z6, n = 616) or placebo (Z3P3, n = 617). The primary endpoint was femoral neck (FN) BMD percentage change from year 3 to 6 in the intent-to-treat (ITT) population. Secondary endpoints included other BMD sites, fractures, biochemical bone turnover markers, and safety. In years 3 to 6, FN-BMD remained constant in Z6 and dropped slightly in Z3P3 (between-treatment difference = 1.04%; 95% confidence interval 0.4 to 1.7; p = 0.0009) but remained above pretreatment levels. Other BMD sites showed similar differences. Biochemical markers remained constant in Z6 but rose slightly in Z3P3, remaining well below pretreatment levels in both. New morphometric vertebral fractures were lower in the Z6 (n = 14) versus Z3P3 (n = 30) group (odds ratio = 0.51; p = 0.035), whereas other fractures were not different. Significantly more Z6 patients had a transient increase in serum creatinine >0.5 mg/dL (0.65% versus 2.94% in Z3P3). Nonsignificant increases in Z6 of atrial fibrillation serious adverse events (2.0% versus 1.1% in Z3P3; p = 0.26) and stroke (3.1% versus 1.5% in Z3P3; p = 0.06) were seen. Postdose symptoms were similar in both groups. Reports of hypertension were significantly lower in Z6 versus Z3P3 (7.8% versus 15.1%, p < 0.001). Small differences in bone density and markers in those who continued versus those who stopped treatment suggest residual effects, and therefore, after 3 years of annual ZOL, many patients may discontinue therapy up to 3 years. However, vertebral fracture reductions suggest that those at high fracture risk, particularly vertebral fracture, may benefit by continued treatment. (ClinicalTrials.gov identifier: NCT00145327). © 2012 American Society for Bone and Mineral Research
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Evidence of efficacy beyond 5 years is limited, whereas rare safety concerns such as ONJ and atypical femur fractures become more common beyond 5 years [67, 92].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [92]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Evidence of efficacy beyond 5 years is limited, whereas rare safety concerns such as ONJ and atypical femur fractures become more common beyond 5 years [67, 92].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [92]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiple imputation after 18+ years
Rubin, D. B. (1996) · Journal of the American Statistical Association · doi:10.1080/01621459.1996.10476908 · Cited by 4,072
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Self-citationOnce-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986
Self-citationMultiple Imputation After 18+ Years
Rubin, D. B. (1996) · Journal of the American Statistical Association · doi:10.2307/2291635 · Cited by 2,686
Cummings, S. R. (1998) · JAMA · doi:10.1001/jama.280.24.2077 · Cited by 2,277
Self-citationShane, E., Burr, D., Abrahamsen, B., Adler, R. A., Brown, T. D., Cheung, A. M., Cosman, F., Curtis, J. R., Dell, R., Dempster, D. W., et al. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1998 · Cited by 2,147
Self-citationZoledronic Acid and Clinical Fractures and Mortality after Hip Fracture
Lyles, K. W., Colón-Emeric, C. S., Magaziner, J. S., Adachi, J. D., Pieper, C. F., Mautalen, C., Hyldstrup, L., Recknor, C., Nordsletten, L., Moore, K. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa074941 · Cited by 2,003
Self-citationEffect of Risedronate on the Risk of Hip Fracture in Elderly Women
McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440503 · Cited by 1,918
Self-citationRisk of New Vertebral Fracture in the Year Following a Fracture
Lindsay, R. (2001) · JAMA · doi:10.1001/jama.285.3.320 · Cited by 1,876
Khosla, S., Burr, D., Cauley, J., Dempster, D. W., Ebeling, P. R., Felsenberg, D., Gagel, R. F., Gilsanz, V., Guise, T., Koka, S., et al. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0707onj · Cited by 1,650
Self-citationBlack, D. M., Schwartz, A. V., Ensrud, K. E., Cauley, J. A., Levis, S., Quandt, S. A., Satterfield, S., Wallace, R. B., Bauer, D. C., Palermo, L., et al. (2006) · JAMA · doi:10.1001/jama.296.24.2927 · Cited by 1,407
Self-citationTen Years' Experience with Alendronate for Osteoporosis in Postmenopausal Women
Bone, H. G., Hosking, D., Devogelaer, J.-P., Tucci, J. R., Emkey, R. D., Tonino, R. P., Rodriguez-Portales, J. A., Downs, R. W., Gupta, J., Santora, A. C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030897 · Cited by 1,347
Chesnut, C. H., Skag, A., Christiansen, C., Recker, R., Stakkestad, J. A., Hoiseth, A., Felsenberg, D., Huss, H., Gilbride, J., Schimmer, R. C., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040325 · Cited by 1,229
Shane, E., Burr, D., Ebeling, P. R., Abrahamsen, B., Adler, R. A., Brown, T. D., Cheung, A. M., Cosman, F., Curtis, J. R., Dell, R., et al. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.253 · Cited by 1,116
Self-citationNevitt, M. C., Ettinger, B., Black, D. M., Stone, K. L., Jamal, S. A., Ensrud, K. E., Segal, M. R., Genant, H. K., & Cummings, S. R. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-10-199805150-00001 · Cited by 841
Self-citationBisphosphonate Use and Atypical Fractures of the Femoral Shaft
Schilcher, J., Michaëlsson, K., & Aspenberg, P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010650 · Cited by 693
EFFECT OF RISEDRONATE ON THE RISK OF HIP FRACTURE IN ELDERLY WOMEN
Lung, R. M. C. C., Eusens, P. I. G., Aul, P., Iller, D. M., Ippel, H. A. Z., Ensen, W. I. G. B., Oux, C. H. R., Dami, S. I. A., Ogelman, I. G. F., Astell, R. I. E., et al. (2001) · Cited by 682
One Year of Alendronate after One Year of Parathyroid Hormone (1–84) for Osteoporosis
Black, D. M., Bilezikian, J. P., Ensrud, K. E., Greenspan, S. L., Palermo, L., Hue, T. F., Lang, T., McGowan, J., & Rosen, C. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050336 · Cited by 614
Self-citationMiller, P. D., Bolognese, M. A., Lewiecki, E. M., McClung, M. R., Ding, B., Austin, M., Liu, Y., & Martín, J. S. (2008) · Bone · doi:10.1016/j.bone.2008.04.007 · Cited by 590
Bisphosphonates and Fractures of the Subtrochanteric or Diaphyseal Femur
Black, D. M., Kelly, M. P., Genant, H. K., Palermo, L., Eastell, R., Bucci-Rechtweg, C. M., Cauley, J. A., Leung, P., Boonen, S., Santora, A. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001086 · Cited by 507
Self-citationBisphosphonate Use and the Risk of Subtrochanteric or Femoral Shaft Fractures in Older Women
Park‐Wyllie, L. Y. (2011) · JAMA · doi:10.1001/jama.2011.190 · Cited by 439
Abrahamsen, B., Eiken, P., & Eastell, R. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.081247 · Cited by 363
Self-citationSchwartz, A. V., Bauer, D. C., Cummings, S. R., Cauley, J. A., Ensrud, K. E., Palermo, L., Wallace, R. B., Hochberg, M. C., Feldstein, A. C., Lombardi, A., et al. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.11 · Cited by 291
Self-citationEnsrud, K. E., Barrett-Connor, E. L., Schwartz, A. V., Santora, A. C., Bauer, D. C., Suryawanshi, S., Feldstein, A. C., Haskell, W. L., Hochberg, M. C., Torner, J. C., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040326 · Cited by 274
Self-citationCharacterization of and Risk Factors for the Acute-Phase Response after Zoledronic Acid
Reid, I. R., Gamble, G. D., Mesenbrink, P. G., Lakatos, P. L., & Black, D. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0597 · Cited by 253
Self-citationBlack, D. M., Palermo, L., Nevitt, M. C., Genant, H. K., Epstein, R. S., Valentin, R. S., & Cummings, S. R. (1995) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650100610 · Cited by 250
Self-citationRizzoli, R., Åkesson, K., Bouxsein, M., Kanis, J. A., Napoli, N., Papapoulos, S. E., Reginster, J.-Y., & Cooper, C. C. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1453-5 · Cited by 244
Fracture risk remains reduced one year after discontinuation of risedronate
Watts, N. B., Chines, A. A., Olszynski, W. P., McKeever, C., McClung, M. R., Zhou, X., & Grauer, A. (2007) · Osteoporosis International · doi:10.1007/s00198-007-0460-7 · Cited by 234
Alendronate and Atrial Fibrillation
Cummings, S. R., Schwartz, A. V., & Black, D. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmc076132 · Cited by 227
Self-citationGreenspan, S. L., Emkey, R. D., Bone, H. G., Weiss, S. R., Bell, N. H., Downs, R. W., McKeever, C., Miller, S. S., Davidson, M., Bolognese, M. A., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-11-200212030-00008 · Cited by 222
Nevitt, M. C. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.1.77 · Cited by 192
Defining Incident Vertebral Deformity: A Prospective Comparison of Several Approaches
Black, D. M., Palermo, L., Nevitt, M. C., Genant, H. K., Christensen, L., & Cummings, S. R. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.1.90 · Cited by 186
Self-citationGlover, S. J., Gall, M., Schönborn‐Kellenberger, O., Wagener, M., Garnero, P., Boonen, S., Cauley, J. A., Black, D. M., Delmas, P. D., & Eastell, R. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080703 · Cited by 167
Self-citationAbrahamsen, B., Eiken, P., & Eastell, R. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1571 · Cited by 159
Self-citationShane, E. J., Burr, D. B., Ebeling, P. R., Abrahamsen, B., Adler, R. A., Brown, T. D., Cheung, A. M., Cosman, F., Curtis, J. R., Dell, R. M., et al. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.416 · Cited by 144
Self-citationGrbic, J. T., Landesberg, R., Lin, S., Mesenbrink, P. G., Reid, I. R., Leung, P., Casas, N., Recknor, C. P., Hua, Y., Delmas, P. D., et al. (2008) · The Journal of the American Dental Association · doi:10.14219/jada.archive.2008.0017 · Cited by 134
Self-citationZoledronic Acid for the Prevention of Bone Loss in Postmenopausal Women With Low Bone Mass
McClung, M. R., Miller, P. D., Recknor, C. P., Mesenbrink, P. G., Bucci-Rechtweg, C. M., & Benhamou, C.-L. (2009) · Obstetrics and Gynecology · doi:10.1097/aog.0b013e3181bdce0a · Cited by 116
Self-citationGrey, A. B., Bolland, M. J., Wattie, D. J., Horne, A. M., Gamble, G. D., & Reid, I. R. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2241 · Cited by 112
Self-citationMelton, L. J., Wenger, D. E., Atkinson, E. J., Achenbach, S. J., Berquist, T. H., Riggs, B. L., Jiang, G., & Eastell, R. (2006) · Osteoporosis International · doi:10.1007/s00198-006-0106-1 · Cited by 35
Self-citation
Flagged first, then by citations
Research works printed but not linked: 2
- Black, 2004, A 5-year randomized trial of the long-term efficacy and safety of alendronate: the FIT Long-term EXtension (FLEX), J Bone Miner Res., 19
- Cosman, 2011, After 3 years of IV zoledronic acid administration, who is at highest risk for subsequent vertebral fractures and who should remain on treatment?, J Bone Miner Res., 26
Cited by
Sorted by citations
Clinician’s Guide to Prevention and Treatment of Osteoporosis
Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2794-2 · Cited by 4,149
“Evidence of efficacy beyond 5 years is limited, whereas rare safety concerns such as ONJ and atypical femur fractures become more common beyond 5 years [67, 92].”
BackgroundSelf-citationRuggiero, S. L., Dodson, T. B., Fantasia, J. E., Goodday, R. H. B., Aghaloo, T. L., Mehrotra, B., & O’Ryan, F. (2014) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2014.04.031 · Cited by 2,975
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF), Kanis, J. A., Cooper, C., Rizzoli, R., & Reginster, J.-Y. (2019) · Osteoporosis International · doi:10.1007/s00198-018-4704-5 · Cited by 1,900
Black, D. M., & Rosen, C. J. (2016) · New England Journal of Medicine · doi:10.1056/nejmcp1513724 · Cited by 1,790
Self-citationThe clinician's guide to prevention and treatment of osteoporosis
LeBoff, M. S., Greenspan, S. L., Insogna, K. L., Lewiecki, E. M., Saag, K. G., Singer, A. J., & Siris, E. S. (2022) · Osteoporosis International · doi:10.1007/s00198-021-05900-y · Cited by 1,487
Metadata
- Authors
- Black, D. M., Reid, I. R., Boonen, S., Bucci-Rechtweg, C., Cauley, J. A., Cosman, F., Cummings, S. R., Hue, T. F., Lippuner, K., Lakatos, P., Leung, P. C., Man, Z., Martinez, R. L. M., Tan, M., Ruzycky, M. E., Su, G., & Eastell, R.
- Affiliations
- University of California, San Francisco (US)
- University of Auckland (NZ)
- KU Leuven (BE)
- Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
- University of Pittsburgh (US)
- Helen Hayes Hospital (US)
- California Pacific Medical Center (US)
- University Hospital of Bern (CH)
- Semmelweis University (HU)
- Chinese University of Hong Kong (HK)
- Centro Médico TIEMPO, Buenos Aires, Argentina
- University of Sheffield (GB)
- Corresponding author
- Black, Dennis M
- ORCID
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-12-08
- Volume
- 27
- Issue
- 2
- Pages
- 243-254
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- PMC
- PMC3427916
- OpenAlex
- W2106406207
- Cited by
- 700
- References
- 40
- Citations by year
- 2026: 18 · 2025: 37 · 2024: 29 · 2023: 45 · 2022: 40 · 2021: 58 · 2020: 53 · 2019: 49 · 2018: 48 · 2017: 54 · 2016: 61 · 2015: 62 · 2014: 50 · 2013: 49 · 2012: 35
- FWCI
- 49.40
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Journal of Bone and Mineral Research (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (UL1TR000005)
- University of California, San Francisco
- Novartis Pharma
- National Center for Research Resources (UL1RR024153)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- zoledronic acid, osteoporosis, postmenopausal women, long-term treatment, bone mineral density, femoral neck, vertebral fractures, fracture risk, bone turnover markers, serum creatinine, atrial fibrillation, stroke, hypertension, bisphosphonates, adverse events
- MeSH terms
- Zoledronic Acid, Aged, Diphosphonates, Female, Follow-Up Studies, Humans, Imidazoles, Osteoporosis, Peptide Fragments, Procollagen, Time Factors, Biomarkers, Bone Density, Incidence, Bone Remodeling, Treatment Outcome, Bone Density Conservation Agents, Osteoporotic Fractures
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
